Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Absorption rate vs. exposure: which is more useful for bioequivalence testing?

T N Tozer1, F Y Bois, W W Hauck

  • 1Department of Pharmacy, School of Pharmacy, University of California, San Francisco 94143-0446, USA.

Pharmaceutical Research
|March 1, 1996
PubMed
Summary

The Cmax/AUClqc metric is not recommended for bioequivalence testing. Focusing on drug exposure, rather than rate and extent of absorption, better ensures similar concentration-time curves between products.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transient Large-Scale Anisotropy in TeV Cosmic Rays due to an Interplanetary Coronal Mass Ejection.

Physical review letters·2026
Same author

Test of CP Symmetry in the Neutral Decays of Λ via J/ψ→ΛΛ[over ¯].

Physical review letters·2026
Same author

Precise Measurement of the Chromoelectric Dipole Moment of the Charm Quark.

Physical review letters·2026
Same author

[Epidemiological and clinical characteristics of pertussis in children at a tertiary pediatric hospital in Shanghai City in 2024].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026
Same author

Precise Measurement of Matter-Antimatter Asymmetry with Entangled Hyperon-Antihyperon Pairs.

Physical review letters·2026
Same author

First Detection of Ultrahigh Energy Emission from Gamma-Ray Binary LS I +61° 303.

Physical review letters·2026

Area of Science:

  • Pharmacokinetics and Drug Development
  • Bioequivalence Study Design
  • Pharmaceutical Analysis

Background:

  • Bioequivalence testing is crucial for generic drug approval.
  • Current methods assess rate and extent of drug absorption.
  • Novel metrics require evaluation for improved bioequivalence assessment.

Purpose of the Study:

  • To evaluate the utility of Cmax/AUClqc in bioequivalence testing.
  • To explore drug exposure as an alternative to rate and extent of absorption.
  • To assess the impact of absorption variability on bioequivalence outcomes.

Main Methods:

  • Simulated bioequivalence trials using a one-compartment model.
  • Incorporated variability in absorption rate (ka) and extent (F).

Related Experiment Videos

  • Utilized Monte Carlo techniques to introduce parameter variability.

    • Main Results:

    • Cmax/AUClqc reflects changes in absorption rate (ka) but not extent (F).
    • Area under the curve (AUClqc) depends on extent (F) but not rate (ka).
    • Cmax showed paradoxical results with significant changes in ka and F.

    Conclusions:

    • Cmax/AUClqc is not a suitable measure for bioequivalence testing.
    • Defining bioequivalence solely by rate and extent of absorption presents challenges.
    • Bioequivalence trials should focus on ensuring similar concentration-time curve shapes, emphasizing drug exposure.